Cancer vaccine manufacturing time could shrink

Key Points:

• Merck CEO Rob Davis expects the manufacturing timeline for the company's personalized cancer vaccine, developed with Moderna, to shorten over time from the current six weeks, potentially enabling treatment for more patients.
• The vaccine targets individual tumor mutations and is paired with Merck's immunotherapy Keytruda to enhance the immune system's ability to attack cancer, with ongoing trials in melanoma, lung, bladder, and kidney cancers.
• Merck recently opened a new 120,000-square-foot research facility in Pennsylvania featuring advanced robotics and AI to accelerate drug research and development, coinciding with preparations for the eventual loss of Keytruda's patent exclusivity.
• To mitigate revenue impacts from Keytruda's patent expiration (starting in 2028), Merck is pursuing a multi-layered strategy including new drug development, combination therapies, and $65 billion in acquisitions and licensing over five years.
• Merck faces legal challenges in Europe and the U.S. over its subcutaneous form of Keytruda, with a Dutch court blocking sales in eight European countries due to a patent suit by Halozyme Therapeutics; Merck plans to appeal while continuing to offer the original intravenous form.